• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthMichael Bloomberg

Michael Bloomberg’s radical plan to cut prescription drug costs

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
January 28, 2020, 6:44 PM ET

In recent years, the rising cost of prescription drugs has been top of mind for consumers and politicians alike. Now Democratic presidential candidate Michael Bloomberg is in on the discussion, citing price increases at a rate five times higher than inflation for 3,400 drugs during the first six months of 2019.

Earlier this week, Bloomberg suggested proposed upending the number of patents a therapy can benefit from as a way to slash the cost of prescription drugs. In fact, Bloomberg’s proposal would restrict new brand name medications to just one patent.

That would limit companies to one 20-year patent period for new branded pharmaceuticals. Right now they can also extend their market dominance by establishing follow-on patents, a process dubbed “evergreening.” Bloomberg’s proposal would take a buzzsaw to that process.

Pharmaceutical companies regularly use patents—including “patent thickets”—to protect their cash cows. For instance, companies commonly seek new patents to iron out wrinkles in a manufacturing procedure for a drug, or tweaks to dosages and delivery mechanisms for a treatment. Along the way? The evergreening thwarts competition from cheaper generic rivals .

There could, however, be other ways to achieve the same goal. For instance, a drug’s initial patent might dictate when generic competitors are allowed on the market (without discounting follow-on patents for ensuing innovations).

And Bloomberg isn’t the only Democratic candidate challenging the drug industry. Sens. Elizabeth Warren and Bernie Sanders, as well as other presidential hopefuls, have endorsed a range of drug pricing reforms spanning the gamut from direct Medicare price negotiations to upending the current biopharma IP system.

A recent Morning Consult poll has Bloomberg surging to 12% support nationally. He’s still a long-shot for the Democratic nomination—but proposals like this from a billionaire could shape the conversation udring the primary stretch.

More must-read stories from Fortune:

—10 stocks that are poised for a stellar 2020
—Will retiring baby boomers crash the stock market?
—Millions have been purged from voter rolls—and may not even realize it
—Inside New York City’s Chinese restaurant crisis
—All of your questions on filing taxes in 2020, answered

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

HealthDietary Supplements
Seed Probiotic Review (2026): Expert Tested and Approved
By Christina SnyderMarch 26, 2026
4 hours ago
wyle
HealthTV
‘The Pitt’ shows an ER getting shut down by a cyberattack that is totally true to life
By Jeffrey Tully, Christian Dameff and The ConversationMarch 26, 2026
5 hours ago
HealthTech
What is tech addiction? A court ruling makes it Big Tech’s next big problem
By Kristin StollerMarch 26, 2026
11 hours ago
HealthDietary Supplements
The Best Colostrum Supplements 2026: Tested and Approved
By Emily PharesMarch 24, 2026
2 days ago
Personal FinanceTaxes
Americans spend $146 billion and 11.6 billion hours doing their taxes, and most of it is just filling out paperwork
By Catherina GioinoMarch 24, 2026
2 days ago
fauci
CommentaryCOVID-19 vaccines
How COVID turned America against science — and what it will take to win it back
By David Blumenthal and James A. MoroneMarch 24, 2026
2 days ago

Most Popular

Success
Palantir’s billionaire CEO says only two kinds of people will succeed in the AI era: trade workers — ‘or you’re neurodivergent’
By Fortune EditorsMarch 24, 2026
2 days ago
C-Suite
'I didn’t want anybody shooting me': Five Guys CEO gave away $1.5 million bonus to employees over botched BOGO burger birthday celebration
By Fortune EditorsMarch 25, 2026
23 hours ago
Magazine
The youngest-ever female CEO of a Fortune 500 company is fighting Trump's cuts to keep Medicaid strong
By Fortune EditorsMarch 24, 2026
2 days ago
Commentary
The Treasury just declared the U.S. insolvent. The media missed it
By Fortune EditorsMarch 23, 2026
3 days ago
Success
JPMorgan’s Jamie Dimon says remote work breeds ‘rope-a-dope politics’ and stunts young workers’ growth
By Fortune EditorsMarch 25, 2026
1 day ago
Environment
Vail Resorts' CEO says it's time to think beyond the $1,000 ski pass that helped build the empire
By Fortune EditorsMarch 26, 2026
11 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.